Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing (GwNICOLA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03109665|
Recruitment Status : Completed
First Posted : April 12, 2017
Last Update Posted : March 21, 2019
Glaucoma is the leading cause of irreversible blindness worldwide. It is caused by damage to the optic nerve between the back of the eye and the brain leading to progressive blindness. The cause is poorly understood but ageing, increased intraocular pressure (IOP) and genetics are all likely to play a role. There is no cure for glaucoma but treatments are available which slow progression. Because vision cannot be restored once lost, early detection, monitoring and early treatment are all essential to preserve visual function.
The condition is diagnosed using a combination of the appearance of the optic nerve on clinical examination or photograph and visual field testing (perimetry). Measurement of IOP and measurement of the thickness of the retinal layers at the back of the eye complement diagnostic decisions.
The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) study does not include perimetry in the series of tests carried out on all participants but does include photography of the optic nerve, measurement of IOP and measurement of retinal thickness. Therefore we propose to invite back participants of the NICOLA study who have abnormal optic discs and high eye pressure to return for perimetry to confirm a diagnosis of glaucoma. Calling back participants for perimetry is essential to make the diagnosis not only for estimating prevalence but also for identifying participant's ill-health.
The primary aim of this study is to quantify the number of participants in the NICOLA study who have glaucoma and report its risk factors. This will allow an estimate of the number of people in the whole of NI with glaucoma. We will also perform a series of novel tests using state-of-the-art technologies to assess if they are better than current tests at diagnosing glaucoma. This may enable better informed decisions about policy decisions in eyecare.
|Condition or disease||Intervention/treatment|
|Glaucoma||Diagnostic Test: SD-OCT Angiography Diagnostic Test: SD-OCT|
Purpose and design: This study will answer the following research questions:
- What is the prevalence of glaucoma within the NICOLA cohort and which systemic and socioeconomic factors influence its prevalence?
- What is the diagnostic accuracy (sensitivity and specificity) of Retinal Nerve Fibre Layer (RNFL) thickness measurements in the diagnosis of glaucoma?
- What is the diagnostic accuracy (sensitivity and specificity) of macular thickness analysis in the diagnosis of glaucoma?
- What is the agreement between intraocular pressure measurement by Ocular Response Analyser (ORA) and Goldmann tonometry?
- What is the correlation between structural (circumpapillary RNFL or macular Ganglion Cell Complex thickness) or functional measurements (retinal oximetry or perimetry) and Optical Coherence Tomography angiography parameters (% vessel density and vessel calibre) in the assessment of glaucoma?
|Study Type :||Observational|
|Actual Enrollment :||129 participants|
|Official Title:||Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing|
|Actual Study Start Date :||March 2, 2017|
|Actual Primary Completion Date :||November 30, 2017|
|Actual Study Completion Date :||November 30, 2017|
Glaucoma within NICOLA
NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
Diagnostic Test: SD-OCT Angiography
Diagnostic Test: SD-OCT
- Prevalence of Glaucoma in Northern Ireland [ Time Frame: 1 day [2 hours] ]Prevalence of Glaucoma in Northern Ireland
- Diagnostic Accuracy of Spectral Domain OCT [ Time Frame: 1 day [2 hours] ]Diagnostic Accuracy of Spectral Domain OCT
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03109665
|Northern Ireland Clinical Research Facility|
|Belfast, Northern Ireland, United Kingdom, BT12 6BA|
|Principal Investigator:||Augusto Azuara-Blanco, PhD, MD||Queens University Belfast|